



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/55, 9/20	A1	(11) International Publication Number: WO 97/47304 (43) International Publication Date: 18 December 1997 (18.12.97)
(21) International Application Number: PCT/EP97/02986 (22) International Filing Date: 6 June 1997 (06.06.97) (30) Priority Data: 96201676.2 14 June 1996 (14.06.96) EP <i>(34) Countries for which the regional or international application was filed:</i> DE et al. (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): GILIS, Paul, Marie, Victor [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DE CONDÉ, Valentin, Florent, Victor [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).		(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: FAST-DISSOLVING GALANTHAMINE HYDROBROMIDE TABLET		
(57) Abstract <p>The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FAST-DISSOLVING GALANTHAMINE HYDROBROMIDE TABLET

5 The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75 : 25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.

10 Galanthamine, a tertiary alkaloid, has been isolated from the bulbs of the Caucasian snowdrops *Galantanus woronowi* (Proskurnina, N. F. and Yakoleva, A. P. 1952, Alkaloids of *Galanthus woronowi*. II. Isolation of a new alkaloid. (In Russian.) Zh. Obschchei Khim. (J. Gen. Chem.) 22, 1899-1902). It has also been isolated from the common snowdrop *Galanthus nivalis* (Boit, 1954). The chemical name of
15 galanthamine is [4aS-(4a α , 6 β , 8aR*)]-4a, 5, 9, 10, 11, 12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a, 3, 2-ef][2]benzazepin-6-ol ; both the base compound and its hydrobromide are laevorotatory. Galanthamine is a well-known acetylcholinesterase inhibitor which is active at nicotinic receptor sites but not on muscarinic receptor sites.
20 It is capable of passing the blood-brain barrier in humans, and presents no severe side effects in therapeutically effective dosages.

Galanthamine has been used extensively as a curare reversal agent in anaesthetic practice in Eastern bloc countries (cf. review by Paskow, 1986) and also experimentally
25 in the West (cf. Bretagne and Valetta, 1965; Wislicki, 1967; Consanitis, 1971).

Galanthamine has been marketed by the Waldheim (Sanochemia Gruppe) as NivalinTM in Germany and Austria since the 1970s for indications such as facial neuralgia.

30 The use of galanthamine or an analogue or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for treating Alzheimer's Dementia (AD) and related dementias has been described in EP-0.236,684 (US-4,663,318). This patent only has a generic disclosure of possible dosage forms of galanthamine.

35 The use of galanthamine for treating alcoholism and the administration via a transdermal transport system (TTS) or patch is disclosed in EP-0.449,247. Similarly, the use of galanthamine in the treatment of nicotine dependence using administration via a transdermal transport system (TTS) or patch is disclosed in WO-94/16708.

A number of applications by E. Snorrason disclose the use of galanthamine, analogues thereof and pharmaceutically acceptable salts thereof for the preparation of medicaments for treating mania (US-5,336,675), chronic fatigue syndrome (CFS) (EP-0,515,302 ; US-5,312,817), and the negative effects of benzodiazepine treatment (EP-0,515,301). In these applications and patents, e.g. in US-5,312,817, a number of specific tablet formulations of galanthamine hydrobromide are given. In particular, these formulations are as follows :

Composition of 1 tablet (60 mg) containing 1 mg galanthamine hydrobromide

10	Galanthamine hydrobromide	0.001 g
	Calcium phosphate	0.032 g
	Lactose	0.005 g
	Wheat Starch	0.0056 g
	Microcrystalline Cellulose	0.015 g
15	Talc	0.0007 g
	Magnesium Stearate	0.0007 g

Composition of 1 tablet (80 mg) containing 5 mg galanthamine hydrobromide ; film-coat composition unknown [Nivalin™, Waldheim, Ltd, Vienna, Austria] (F 3)

20	Galanthamine hydrobromide	0.005 g
	Calcium phosphate	0.024 g
	Lactose	0.004 g
	Wheat Starch	0.004 g
	Microcrystalline Cellulose	0.04 g
25	Talc	0.002 g
	Magnesium Stearate	0.001 g

Composition of 1 tablet (120 mg) containing 10 mg galanthamine hydrobromide

	Galanthamine hydrobromide	0.010 g
30	Lactose	0.040 g
	Wheat Starch	0.0234 g
	Microcrystalline Cellulose	0.0374 g
	Talc	0.0036 g
	Magnesium Stearate	0.0012 g
35	Gelatin	0.0044 g

These tablet formulations can be prepared using wet granulation processes.

The dissolution (USP 23, <711> Dissolution, pp 1791-1793, Apparatus 2 (paddle, 50 rpm; 500 ml water or aqueous buffer at 37 °C)) of the commercially available Nivalin™ 5 mg film-coated tablet (F3) is as follows :

Time (min)	Calculated concentration (% w/w) of the active dose				
	H ₂ O	pH 4.5 USP	pH 6.5 USP	pH 7.5 USP	0.1N HCl
0	0.00	0.00	0.00	0.00	0.00
5	6.23	21.38	5.25	12.80	41.95
15	51.75	86.33	43.88	37.70	91.05
30	80.88	97.63	79.78	66.18	98.88
45	93.28	98.60	87.88	82.70	102.08
60	100.75	99.20	90.70	90.93	101.63

5 In order to obtain government approval to market a drug, one must not only show that the active ingredient has the stated activity and is safe to use, but it is also necessary to show that the formulation of the active ingredient will give a reproducible result in various patients. For example, in the case of solid formulations shaped as tablets, it is a prerequisite that the tablets disintegrate and dissolve within a particular period of time to a particular degree. In the present case, novel galanthamine hydrobromide tablets having a dissolution of at least 80 % after 30 minutes (Q = 80 % after 30') (USP 23, <711> Dissolution, pp 1791-1793, Apparatus 2 (paddle, 50 rpm; 500 ml purified water at 37 °C)) are provided. Compliance with this dissolution specification is only met by using a particular diluent containing a disintegrant, and a second disintegrant.

20 Thus the present invention relates to a tablet comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75 : 25) as a diluent, and a disintegrant. Said tablets have a dissolution of at least 80 % after 30 minutes (Q = 80 % after 30') (USP 23, <711> Dissolution, pp 1791-1793, Apparatus 2 (paddle, 50 rpm)).

25 Initial experiments started out using either lactose anhydrous or lactose monohydrate as diluent, and either powdered cellulose or microcrystalline cellulose as disintegrant (see tablet formulations F1 and F2 in the Experimental Part). A particular problem which occurred during feeding the dry blend into the tablet press for direct compression, was segregation of the tablet excipients, thus causing the tablets to have a variable composition. In addition, the tablets formulations F1 and F2 did not comply at Stage 1

30

with the dissolution specification of $Q = 80\%$ after 30'. In order to solve the perceived problems, the diluent was substituted for a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25), commercially available as Microcelac™. In addition to having a reduced tendency to segregate during feeding into the tablet press, the dry blend comprising the above diluent was further found to have excellent rheological properties (flowability), as well as to be easily miscible with the active ingredient and other tablet excipients. The dissolution specification was not met, however, unless a disintegrant having a large coefficient of expansion was employed, more in particular, if an insoluble or poorly soluble cross-linked polymer such as, for example, crospolyvidone or croscarmellose was employed. The amount of said disintegrants in the fast-dissolving tablets according to the present invention conveniently ranges from about 3 to about 8 % (w/w), preferably about 5 % (w/w).

In order to make the blending and the direct compression processes easier to perform, the carrier further comprises a glidant and a lubricant. Preferably, the glidant is colloidal anhydrous silica and the lubricant is magnesium stearate. In the initial experiments (see F1 and F2), talc was used as a glidant and sodium lauryl sulphate as a wetting agent/lubricant. The former was found to affect the dissolution properties of the tablets adversely (retarding the dissolution of the active ingredient) and the latter was found to be entirely superfluous and easy to omit from the tablet formulation.

Fast-dissolving tablets according to the present invention comprise by weight based on the total weight of the tablet core :

- (a) from 2 to 10% galanthamine hydrobromide (1:1);
- (b) from 83 to 93% spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25);
- (c) from 0.1 to 0.4% glidant;
- (d) from 3 to 8% insoluble crosslinked polymeric disintegrant; and
- (e) from 0.2 to 1% lubricant.

In particular, the tablets comprise :

- (a) about 2 to 10% galanthamine hydrobromide (1:1);
- (b) about 83 to 93% spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25);
- (c) about 0.2% colloidal anhydrous silica;
- (d) about 5% crospolyvidone; and
- (e) about 0.5% magnesium stearate.

The fast-dissolving galanthamine hydrobromide (1:1) tablets according to the present invention may in addition include other optional excipients such as, for example, flavors, sweeteners and colors.

- 5 Tablets of galanthamine hydrobromide (1:1) are conveniently film-coated following art-known coating procedures. Film-coated tablets are easier to swallow than uncoated tablet cores, are usually easier to distinguish from other tablets - in particular when the film-coat contains a dye or a pigment -, and may furthermore have an improved stability (shelf-life). In the instant case, a mixture comprising a film-forming polymer and a
10 plasticizer, in particular hydroxypropyl methylcellulose and a polyethylene glycol, e.g. macrogol 6000, may be employed for film-coating tablet cores as described hereinbefore. Of particular importance in the case of fast-dissolving tablets, is the requirement that the film-coat should not adversely affect the disintegration and dissolution of the active ingredient from the tablet. Therefore, the weight of the film-
15 coat conveniently is in the range of 3 to 8 %, particularly 4 to 7.5 %, of the uncoated tablet core. As illustrated in the experimental part both the uncoated tablet cores and the film-coated tablets according to the present invention (F5, F6, F7) both comply with the dissolution requirement of Q = 80 % after 30' (USP).
- 20 The tablets according to the present invention are suitable as unit dose forms for oral administration to patients in need of galanthamine therapy. The tablets conveniently comprise from 2 to 20 mg galanthamine (2.563 to 25.63 mg galanthamine hydrobromide (1:1)), in particular from 4 to 16 mg galanthamine (5.026 to 20.506 mg galanthamine hydrobromide (1:1)). They are best administered three times daily (t.i.d),
25 approximately every eight hours, or two times daily (b.i.d), approximately every 12 hours, as these dosage regimens give therapeutic plasma levels of the active ingredient throughout the day.

- The present invention is also concerned with a process of preparing fast-dissolving galanthamine hydrobromide (1:1) tablets, comprising the steps of :
- 30 (i) dry blending the active ingredient, the disintegrant and the optional glidant with the diluent;
- (ii) optionally mixing the lubricant with the mixture obtained in step (i);
- (iii) compressing the mixture obtained in step (i) or in step (ii) in the dry state into a
35 tablet; and
- (iv) optionally film-coating the tablet obtained in step (iii).

The dry blending can conveniently be performed in a planetary mixer ; the direct compression on a tablet press; and the film-coating in a coating pan.

Experimental part

5 Example 1 : Direct compression tablet formulation (F1)

Ingredients :

	galanthamine hydrobromide	5 mg
	lactose (anhydrous)	70 mg
	powdered cellulose	19 mg
10	talc	4 mg
	sodium lauryl sulphate	1 mg
	colloidal anhydrous silica	0.5 mg
	magnesium stearate	0.5 mg
15	<i>total weight</i>	<i>100 mg</i>

Preparation :

The ingredients were intimately mixed in a planetary mixer and compressed in a tableting machine, thus preparing tablets of 100 mg each.

20 Example 2 : Direct compression film-coated tablet formulation (F2)

Ingredients :

	galanthamine hydrobromide	5.13 mg (4 mg galanthamine)
	lactose monohydrate	55.11 mg
	microcrystalline cellulose	15.2 mg
25	talc	3.2 mg
	sodium lauryl sulphate	0.8 mg
	colloidal anhydrous silica	0.16 mg
	magnesium stearate	0.4 mg
	<i>core weight</i>	<i>80 mg</i>
30	hypromellose 2910 5 mPa s	1.8 mg
	talc	0.8 mg
	titanium dioxide (E 171)	0.1 mg
	Macrogol 6000	0.3 mg
	purified water*	17 mg
35	<i>film-coated weight</i>	<i>3 mg</i>
	<i>total weight</i>	<i>83 mg</i>

*This component is not present in the final product.

Preparation :

The ingredients were intimately mixed in a planetary mixer and compressed in a tableting machine, thus preparing tablets of 80 mg each. The tablet cores were then film-coated in a coating pan.

5

Example 3 : Direct compression film-coated tablet formulation (F5)*Ingredients :*

	galanthamine hydrobromide	5.126 mg (4 mg galanthamine)
	spray-dried mixture of lactose monohydrate	221.194 mg
10	and microcrystalline cellulose (75:25)	
	crospolyvidone	12 mg
	colloidal anhydrous silica	0.48 mg
	magnesium stearate	1.2 mg
	core total weight	240 mg
15	hypromellose 2910 5 mPa.s	5.4 mg
	talc	2.4 mg
	titanium dioxide (E 171)	0.3 mg
	Macrogol 6000	0.9 mg
20	purified water*	51 mg
	film-coat weight	9 mg
	total weight	249 mg

*This component is not present in the final product.

25 *Preparation :*

The ingredients were intimately mixed in a planetary mixer and compressed in a tableting machine, thus preparing tablets of 240 mg each. The tablet cores were then film-coated in a coating pan.

30 Example 4 : Direct compression film-coated tablet formulation (F6)*Ingredients :*

	galanthamine hydrobromide	23.069 mg (18 mg galanthamine)
	spray-dried mixture of lactose monohydrate	203.251 mg
	and microcrystalline cellulose (75:25)	
35	crospolyvidone	12 mg
	colloidal anhydrous silica	0.48 mg
	magnesium stearate	1.2 mg
	core total weight	240 mg

	hypromellose 2910 5 mPa.s	5.4 mg
	talc	2.4 mg
	titanium dioxide (E 171)	0.3 mg
5	Macrogol 6000	0.9 mg
	purified water*	51 mg
	<i>film-coat weight</i>	<i>9 mg</i>
	<i>total weight</i>	<i>249 mg</i>

*This component is not present in the final product.

10

Preparation :

The ingredients were intimately mixed in a planetary mixer and compressed in a tableting machine, thus preparing tablets of 240 mg each. The tablet cores were then film-coated in a coating pan.

15

Example 5 : Direct compression film-coated tablet formulations of various strength
(F7a, F7b, F7c, F7d)

<i>Ingredients</i> (in mg unless indicated otherwise) :		F7a	F7b	F7c	F7d
20	galanthamine hydrobromide	5.126	10.253	15.379	20.506
	(galanthamine)	(4)	(8)	(12)	(16)
	spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25)	51.454	102.907	154.361	205.814
	crospolyvidone	3	6	9	12
	colloidal anhydrous silica	0.12	0.24	0.36	0.48
25	magnesium stearate	0.3	0.6	0.9	1.2
	<i>core total weight</i>	<i>60</i>	<i>120</i>	<i>180</i>	<i>240</i>
	hypromellose 2910 5 mPa.s	2.5	4	5	6 *
	propylene glycol (µl)	0.603	0.965	1.207	1.448
30	talc	0.5	0.8	1	1.2
	titanium dioxide (E 171)	0.75	1.2	1.5	1.8
	colorant(s)	0.0032	0.013	0.505	0.130
	purified water*	26.875	43	53.75	64.5
	<i>film-coat weight</i>	<i>4.3562</i>	<i>6.978</i>	<i>9.212</i>	<i>10.578</i>
35	<i>total weight</i>	<i>64.3562</i>	<i>126.978</i>	<i>189.212</i>	<i>250.578</i>

*This component is not present in the final product.

Preparation :

The ingredients were intimately mixed in a planetary mixer and compressed in a tableting machine, thus preparing tablets of 60, 120, 180, and 240 mg. The tablet cores were then film-coated in a coating pan.

5

Example 6

Comparative in-vitro dissolutions studies were performed on tablet formulations F1, F2, F5 (uncoated), F5 (film-coated), F6 (uncoated), F6 (film-coated) and F7a-d (film-coated). The medium was 500 ml of purified water at 37°C in Apparatus 2 (USP 23, <711> Dissolution, pp. 1791-1793) (paddle, 50 rpm).

10

The following results were obtained:

F1

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	77.85	59.10	72.40	74.48	76.23	61.35	70.23
15	87.33	78.88	86.73	83.40	89.08	76.33	83.62
30	90.98	84.15	88.40	87.43	91.78	82.20	87.49
45	92.78	87.28	90.30	89.83	93.30	85.83	89.88
60	93.58	88.95	91.00	92.35	96.35	89.83	92.01

15 *F2*

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	34.48	24.42	33.92	37.35	33.67	33.33	32.86
15	85.23	75.32	79.39	85.23	84.26	73.93	80.56
30	90.55	84.99	87.31	90.30	90.64	83.11	87.82
45	92.84	88.89	90.45	92.47	93.49	88.38	91.09
60	94.40	90.69	92.28	93.91	94.62	89.74	92.60

F5 uncoated

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	95.59	96.71	95.10	96.63	95.81	96.85	96.11
15	96.15	97.22	97.37	97.29	97.27	97.39	97.11
30	97.46	97.27	97.49	97.56	97.66	97.68	97.52
45	98.10	97.51	97.68	97.73	98.12	98.27	97.90
60	98.17	97.59	97.61	98.12	98.00	98.29	97.96

F5 film-coated

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	86.27	81.08	89.37	87.81	92.95	86.93	87.40
15	92.76	93.29	92.90	93.34	97.46	93.27	93.84
30	97.27	96.24	95.07	95.20	98.05	94.61	96.07
45	98.12	97.51	96.27	96.63	98.20	95.68	97.07
60	98.05	97.66	96.49	96.66	98.22	96.61	97.28

5 *F6 uncoated*

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	94.02	94.33	93.18	93.59	95.13	93.29	93.92
15	97.17	97.08	97.84	97.34	97.82	97.47	97.45
30	97.49	97.64	98.53	98.03	98.68	97.62	98.00
45	98.12	98.34	98.92	98.36	99.46	98.21	98.57
60	98.53	98.38	99.61	100.09	100.55	98.40	99.26

F6 film-coated

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	94.61	77.70	95.63	90.51	83.90	78.94	86.88
15	98.14	96.93	99.81	97.32	96.25	95.86	97.39
30	98.81	99.05	100.61	99.51	99.29	97.97	99.21
45	99.74	99.61	100.70	99.59	100.13	99.90	99.95
60	100.24	100.76	100.74	100.13	100.52	100.57	100.50

F7a film-coated

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10	79.2	83.9	87.1	86.4	81.0	84.7	83.7
20	88.3	93	94.5	93.4	89.8	93.7	92.1
30	91.9	96.0	96.5	95.9	92.8	96.2	94.9
45	93.5	97.5	97.1	97.2	94.5	97.8	96.3
60	94.0	98.8	97.9	98.0	95.4	98.7	97.1

5 *F7b film-coated*

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10	77.2	73.0	83.3	82.3	82.1	80.7	79.8
20	88.1	86.4	91.6	91.2	93.9	90.6	90.3
30	92.4	91.1	93.9	93.4	96.4	93.7	93.5
45	94.8	93.3	94.7	94.9	98.2	95.0	95.1
60	96.1	95.2	95.7	95.7	99.2	95.9	96.3

F7c film-coated

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10	85.9	92.1	93.4	92.0	95.8	93.2	92.1
20	96.0	98.3	98.3	97.8	100.2	99.7	98.4
30	99.6	99.5	98.6	98.6	100.4	100.4	99.5
45	101.3	100.2	98.8	99.1	100.8	101.0	100.2
60	102.0	100.5	99.0	99.2	100.8	101.0	100.4

F7d film-coated

Time (min)	Calculated concentration (% w/w) of the active dose						
	sample 1	sample 2	sample 3	sample 4	sample 5	sample 6	average
0	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10	70.1	82.1	77.8	81.6	82.6	79.9	79.0
20	86.0	95.0	90.6	93.3	90.8	92.6	91.4
30	94.1	99.0	94.4	96.9	94.0	97.1	95.9
45	98.1	101.8	99.5	98.5	95.7	99.2	98.8
60	102.3	102.1	98.2	99.4	96.5	100.3	99.8

- 5 Neither of F1 and F2 comply at stage 1 with the dissolution specification $Q = 80\%$ at 30 minutes; both F5 (uncoated), F5 (film-coated), F6 (uncoated), F6 (film-coated) and F7a-d (film-coated) comply at stage 1 with the dissolution specification $Q = 80\%$ at 30 minutes.

Claims

1. A tablet comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier,
5 characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75 : 25) as a diluent, and a disintegrant.
2. A tablet according to claim 1 wherein the disintegrant is croscopolvidone or
10 croscarmellose.
3. A tablet according to claim 1 or 2 wherein the carrier further comprises a glidant and a lubricant.
- 15 4. A tablet according to claim 3 wherein the glidant is colloidal anhydrous silica and wherein the lubricant is magnesium stearate.
5. A tablet according to any one of claims 1, 2, 3 or 4 comprising by weight based on the total weight :
20 (a) from 2 to 10% galanthamine hydrobromide (1:1);
(b) from 83 to 93% spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25);
(c) from 0.1 to 0.4% glidant;
(d) from 3 to 8% insoluble crosslinked polymeric disintegrant; and
25 (e) from 0.2 to 1% lubricant.
6. A tablet according to claim 5 comprising
(a) about 2 to 10% galanthamine hydrobromide (1:1);
(b) about 83 to 93% spray-dried mixture of lactose monohydrate and
30 microcrystalline cellulose (75:25);
(c) about 0.2% colloidal anhydrous silica;
(d) about 5% croscopolvidone; and
(e) about 0.5% magnesium stearate.
- 35 7. A tablet according to any one of claims 1, 2, 3, 4, 5 or 6 which is film-coated.
8. A tablet according to claim 7 wherein the film-coat comprises a film-forming polymer and a plasticizer.

9. A tablet according to claim 8 wherein the film-coat weighs from about 3 % to about 8 % of the uncoated tablet core.
10. A process of preparing a tablet according to any one of claims 1 to 9 comprising the steps of :
- (i) dry blending the active ingredient, the disintegrant and the optional glidant with the diluent;
 - (ii) optionally mixing the lubricant with the mixture obtained in step (i);
 - (iii) compressing the mixture obtained in step (i) or in step (ii) in the dry state into a tablet; and
 - (iv) optionally film-coating the tablet obtained in step (iii).

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/EP 97/02986

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/55 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 693 750 A (KURT H. BAUER ET AL.) 15 September 1987 see the whole document ---	1-10
Y	EP 0 515 302 A (SNORRASON, ERNIR) 25 November 1992 cited in the application see the whole document ---	1-10
Y	EP 0 515 301 A (SNORRASON, ERNIR) 25 November 1992 cited in the application see the whole document -----	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 September 1997

Date of mailing of the international search report

26.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4693750 A	15-09-87	DE 3506276 C	24-04-86
		EP 0192080 A	27-08-86
		JP 1932547 C	26-05-95
		JP 6055670 B	27-07-94
		JP 61194016 A	28-08-86

EP 515302 A	25-11-92	AU 663086 B	28-09-95
		AU 1873692 A	30-12-92
		AU 1886392 A	30-12-92
		CA 2062094 A	15-11-92
		CA 2103022 A	15-11-92
		WO 9220328 A	26-11-92
		EP 0584285 A	02-03-94
		JP 6507621 T	01-09-94
		NO 934103 A	12-11-93
		NZ 242743 A	24-02-97
		US 5589475 A	31-12-96
		US 5633238 A	27-05-97
		US 5336675 A	09-08-94
		AU 658424 B	13-04-95
		WO 9220327 A	26-11-92
		EP 0515301 A	25-11-92
		EP 0584185 A	02-03-94
		JP 6507617 T	01-09-94
		NO 934104 A	12-11-93
		NZ 242744 A	24-02-97
		US 5312817 A	17-05-94

EP 515301 A	25-11-92	AU 1873692 A	30-12-92
		AU 658424 B	13-04-95
		AU 1886392 A	30-12-92
		WO 9220327 A	26-11-92
		EP 0584185 A	02-03-94
		JP 6507617 T	01-09-94
		NO 934104 A	12-11-93
		NZ 242744 A	24-02-97
		US 5312817 A	17-05-94
		AU 663086 B	28-09-95
		CA 2062094 A	15-11-92
		CA 2103022 A	15-11-92

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02986

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 515301 A		WO 9220328 A	26-11-92
		EP 0515302 A	25-11-92
		EP 0584285 A	02-03-94
		JP 6507621 T	01-09-94
		NO 934103 A	12-11-93
		NZ 242743 A	24-02-97
		US 5589475 A	31-12-96
		US 5633238 A	27-05-97
		US 5336675 A	09-08-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03189

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0689844	A	03-01-1996	HU 72055 A	28-03-1996
WO 9412217	A	09-06-1994	US 5332582 A	26-07-1994
			AU 672862 B	17-10-1996
			AU 5684194 A	22-06-1994
			CA 2150554 A	09-06-1994
			CN 1103316 A	07-06-1995
			EP 0674528 A	04-10-1995
			JP 8503951 T	30-04-1996
			US 5538721 A	23-07-1996
			ZA 9308945 A	02-08-1994
WO 9014082	A	29-11-1990	FR 2647015 A	23-11-1990
			AU 5668790 A	18-12-1990
			IT 1241141 B	29-12-1993
EP 0300526	A	25-01-1989	AU 611692 B	20-06-1991
			AU 1835288 A	05-01-1989
			CA 1322172 A	14-09-1993
			DK 360988 A	02-01-1989
			FI 883136 A	02-01-1989
			JP 1045319 A	17-02-1989
			PH 26159 A	18-03-1992
			PT 87880 A	30-06-1989
			RU 2016567 C	30-07-1994
			US 4956351 A	11-09-1990
WO 9718245	A	22-05-1997	AU 7637296 A	05-06-1997
EP 0614666	A	14-09-1994	US 5298410 A	29-03-1994
			AU 660843 B	06-07-1995
			AU 4616293 A	01-09-1994
			CA 2106519 A	26-08-1994
			CZ 9400381 A	19-10-1994
			FI 940909 A	26-08-1994
			HU 71586 A	28-12-1995
			IL 108777 A	08-02-1998
			JP 6256222 A	13-09-1994
			MX 9305528 A	31-08-1994
			NO 940663 A	26-08-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03189

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0614666 A		NZ 248590 A	26-07-1995
		SK 23294 A	08-02-1995
		US 5389381 A	14-02-1995
		US 5334382 A	02-08-1994
		US 5529915 A	25-06-1996
US 5472954 A	05-12-1995	US 5324718 A	28-06-1994
		EP 0579435 A	19-01-1994
		SG 49182 A	18-05-1998
US 4351846 A	28-09-1982	JP 1307595 C	13-03-1986
		JP 56158760 A	07-12-1981
		JP 60033430 B	02-08-1985
		DE 3118360 A	15-07-1982
		FR 2482097 A	13-11-1981
		GB 2075976 A, B	25-11-1981
US 4956351 A	11-09-1990	AU 611692 B	20-06-1991
		AU 1835288 A	05-01-1989
		CA 1322172 A	14-09-1993
		DK 360988 A	02-01-1989
		EP 0300526 A	25-01-1989
		FI 883136 A	02-01-1989
		JP 1045319 A	17-02-1989
		PH 26159 A	18-03-1992
		PT 87880 A	30-06-1989
		RU 2016567 C	30-07-1994
US 5206025 A	27-04-1993	FR 2647343 A	30-11-1990
		AU 623779 B	21-05-1992
		AU 5582890 A	10-01-1991
		AU 631888 B	10-12-1992
		AU 5743390 A	18-12-1990
		CA 2017355 A	24-11-1990
		CA 2017360 A	24-11-1990
		DE 69005359 D	03-02-1994
		DE 69005359 T	05-05-1994
		DK 399902 T	14-02-1994
		DK 399903 T	08-02-1993
		EP 0399902 A	28-11-1990

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.